BioSpace News Archive

Recently, the results of the Phase I study for iparomlimab, developed by Qilu Pharmaceutical Co., Ltd. were published online in the academic journal Frontiers in Immunology.

Celldex Therapeutics, Inc. announced positive topline results from the Company’s Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria refractory to antihistamines, including patients who received prior biologics.

BioNTech SE reported financial results for the three and nine months ended September 30, 2023, and provided an update on its corporate progress.

NRx Pharmaceuticals, Inc. and Nephron Pharmaceuticals, Inc. announced the signing of a development and manufacturing agreement to manufacture a presentation of ketamine suitable for treating suicidal depression, an urgent public health need.

Protalix BioTherapeutics, Inc. reported financial results for the third quarter ended September 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

ProQR Therapeutics N.V. announced it has further strengthened its leading intellectual property estate with the issuance of a new patent in the United States and that it has successfully defended against an opposition to its IP in Japan.

Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting and the development of clinical trials, announces today that the first patients in its phase 2 multiple-dose psilocybin study have received treatment.

Helius Medical Technologies, Inc. announced the publication of a white paper demonstrating that rehabilitative treatment with the Portable Neuromodulation Stimulator can drastically improve return-to-work outcomes for patients suffering from TBI.

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, announced today that it will report third quarter 2023 financial results on Monday, November 13, 2023 before the open of the financial markets.

EvolveImmune Therapeutics announced that new preclinical and translational data highlighting EV-104 and EV-106, two programs utilizing EVOLVE, the company’s proprietary costimulatory T cell engager platform were presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer.